Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis

Zeng, Siyuan; Daju, Liu; Yu, Yongai; Zou, Lei; Jin, Xiance; Liu, Bing; Liu, Lifeng

doi:10.3389/fphar.2023.1111061

Cited by 4 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 23 , 24 ] By blocking the interaction between PD-1 receptors on T-cells and PD-L1 on tumor cells, these agents reinvigorate the immune system ability to recognize and attack cancer cells. [ 25 , 26 ] This systematic review and meta-analysis aimed to synthesize available evidence on the efficacy and safety of PD-1/PD-L1 inhibitors in recurrent OC, providing a comprehensive understanding of their therapeutic potential and limitations.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis

Chen,

Liu,

et al. 2024

Medicine

View full text Add to dashboard Cite

Background: Recurrent ovarian cancer (OC) presents a significant therapeutic challenge with limited treatment success. Programmed cell death protein 1 (PD-1/PD-L1) immune checkpoint inhibitors have emerged as a potential treatment avenue, necessitating a systematic review and meta-analysis to evaluate their efficacy and safety. Methods: Adhering to preferred reporting items for systematic reviews and meta-analyses guidelines, we conducted a comprehensive literature search across PubMed, Embase, Web of Science, and Cochrane Library, culminating in the inclusion of studies focusing on the treatment of recurrent OC with PD-1/PD-L1 inhibitors. Studies were evaluated using the Newcastle-Ottawa Scale and analyzed using fixed or random effects models depending on heterogeneity levels. Results: Our search yielded 1215 articles, with 6 meeting the inclusion criteria for final analysis. Studies varied in size and reported median age, overall survival (OS), progression-free survival (PFS), and adverse events. The meta-analysis showed improved Objective Response Rates (ORR), Disease Control Rate (DCR), and PFS in patients treated with PD-1/PD-L1 inhibitors. The overall adverse event rate was 17.9%, indicating a need for careful patient selection and monitoring. No significant publication bias was detected, enhancing the reliability of our findings. Conclusions: PD-1/PD-L1 inhibitors offer a promising treatment option for recurrent OC, improving ORR, DCR, and PFS. However, the higher incidence of adverse events necessitates a cautious approach to their use. Future research should focus on long-term outcomes, biomarker identification, and optimal combination therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis

Chen,

Liu,

et al. 2024

Medicine

View full text Add to dashboard Cite

show abstract

“…Currently, several antibodies against the cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) or programmed cell death 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1) signaling pathway are approved for the treatment of various cancers ( 6 ). ICIs have achieved significant clinical results in melanoma and non-small cell lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer

Zhang,

Mi,

Xin

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

Breast cancer is characterized by a high incidence rate and its treatment challenges, particularly in certain subtypes. Consequently, there is an urgent need for the development of novel therapeutic approaches. Immunotherapy utilizing immune checkpoint inhibitors (ICIs) is currently gaining momentum for the treatment of breast cancer. Substantial progress has been made in clinical studies employing cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) inhibitors for breast cancer, but the cure rates are relatively low. To improve the efficacy of CTLA-4-based therapy for breast cancer, further research is imperative to explore more effective immune-based treatment strategies. In addition to monotherapy, CTLA-4 inhibitors are also being investigated in combination with other ICIs or alternative medications. However, it should be noted that immune-based treatments may cause adverse events. This review focuses on the mechanisms of CTLA-4 inhibitor monotherapy or combination therapy in breast cancer. We systematically summarize the latest research and clinical advances in CTLA-4-based immunotherapy for breast cancer, providing new perspectives on the treatment of breast cancer. In addition, this review highlights the immune-related adverse events (irAEs) associated with CTLA-4 inhibitors, providing insights into the development of appropriate clinical tumor immunotherapy regimens and intervention strategies.

show abstract

Research Progress of Hydrogel in the Application of Gynecologic Malignant Tumor Treatment

韩

2023

ACM

View full text Add to dashboard Cite

Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of recurrent and refractory ovarian cancer: A systematic review and a meta-analysis

Cited by 4 publications

References 30 publications

Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis

Efficacy and safety of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of recurrent ovarian cancer: A systematic review and meta-analysis

Recent research and clinical progress of CTLA-4-based immunotherapy for breast cancer

Research Progress of Hydrogel in the Application of Gynecologic Malignant Tumor Treatment

Contact Info

Product

Resources

About